Overview: FISH C-MYC TestIntroduction: The FISH C-MYC Test detects C-MYC gene abnormalities linked to lymphomas, causing lymph node swelling or fatigue. Following 2023 ASH guidelines, it uses fluorescence in situ hybridization (FISH) for high specificity, aiding in cancer screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in cytogenetics for patients with suspected lymphomas.
Other Names: C-MYC FISH Assay, Lymphoma Gene Test.
FDA Status: Laboratory-developed test (LDT), meeting cytogenetics standards for diagnostic accuracy.
Historical Milestone: C-MYC testing began in the 1980s with lymphoma research. FISH assays emerged in the 1990s, and by the 2000s, standardized probes improved accuracy.
Purpose: Diagnoses lymphomas, guides treatment, and monitors C-MYC gene abnormalities in patients with lymph node swelling or fatigue.
Test Parameters: 1. C-MYC Gene
Pretest Condition: No fasting required. Collect whole blood, bone marrow, or tissue at any time. Report symptoms like lymph node swelling or fatigue, and list medications.
Specimen: 2-5 mL whole blood (EDTA), 2-5 mL bone marrow (EDTA), or 0.5-2 cma³ tissue (FFPE). Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document lymph node swelling, fatigue, or history of lymphomas. Include current medications, especially chemotherapeutics.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for cancer therapy.
Procedural Considerations: Uses FISH to detect C-MYC gene abnormalities. Results are available in 3-5 days, supporting clinical decisions.
Factors Affecting Result Accuracy: Poor sample quality or low cell yield can affect results. Rare abnormalities may require additional testing.
Clinical Significance: Positive C-MYC abnormalities confirm lymphoma, prompting treatment. Negative results may require further genetic testing.
Specialist Consultation: Consult a hematologist or oncologist for result interpretation.
Additional Supporting Tests: Bone marrow biopsy, flow cytometry, or PET scan to confirm lymphoma.
Test Limitations: False negatives may occur with rare abnormalities. Results require clinical correlation.
References: ASH Lymphoma Guidelines, 2023; Blood, Swerdlow SH, 2022.
